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1. THE TERM AND ITS MEANING 
The term pharmacokinetics was first introduced by F. H. Dost in 1953 in his text, Der 
BliitspiegeI-Kinetic der Konzentrationsablaiife in der Frieslauffliissigkeit (Dost, 1953). 
However, some of the subject matter was published before the word was coined. It is also 
of interest that the first English language review of the subject matter, published in 1961, 
was entitled the Kinetics of Drug Absorption, Distribution, Metabolism and Excretion and 
did not include the word pharmacokinetics (Nelson, 1961). 
Pharmacokinetics has been defined in a number of ways. Literally, the word means the 
application of kinetics to pharmakon, the Greek word for drugs and poisons. Kinetics is 
that branch of knowledge which involves the change of one or more variables as a 
function of time. The purpose of pharmacokinetics is to study the time course of drug 
and metabolite concentrations or amounts in biological fluids, tissues and excreta, and 
also of pharmacological response, and to construct suitable models to interpret such 
data. In pharmacokinetics, the data are analyzed using a mathematical representation of 
a part or the whole of an organism. Broadly then, the purposes of pharmacokinetics are 
to reduce data to a number of meaningful parameter values, and to use the reduced data 
to predict either the results of future experiments or the results of a host of studies which 
would be too costly and time-consuming to complete (Wagner, 1968 and 1975). A similar 
definition has been given by other authors (Gibaldi and Levy, 1976) as follows: 'Pharma- 
cokinetics is concerned with the study and characterization of the time course of drug 
absorption, distribution, metabolism and excretion, and with the relationship of these 
processes to the intensity and time course of therapeutic and adverse effects of drugs. It 
involves the application of mathematical and biochemical techniques in a physiologic 
and pharmacologic context.' 
In this historical review emphasis is placed on pharmacokinetic theory and not on 
applications of that theory. 
2. ORIGINS OF THE SUBJECT MA'I~ER 
The origins of the subject matter of pharmacokinetics are both multinational and 
multidisciplinary. 
Buchanan in England in 1847, while describing ether anesthesia, clearly understood 
that the brain content of anesthetics determined the depth of narcosis and depended 
upon the arterial concentration, which in turn was related to the strength of the inhaled 
mixture. Moreover, he pointed out that for short ether inhalations, the speed of recovery 
was related to redistribution of ether in the body. He calculated the amounts of ether 
inhaled, exhaled and retained during induction with this short acting anesthetic (Bucha- 
nan, 1947; Butler, 1964). 
From Germany, in 1913, Michaelis and Menten published what is now known as the 
Michaelis-Menten equation for describing enzyme kinetics. In pharmacokinetics, this 
same equation is used to describe the elimination kinetics of ethanol, salicylate, pheny- 
toin and several other drugs (Michaelis and Menten, 1913). 
537 
538 JOHN G. WAGNER 
Swedish investigators, Widmark and Tandberg, in 1924 published equations appro- 
priate to what are now called: (a) the one-compartment open model with bolus intra- 
venous injection and multiple doses administered at uniform time intervals, and (b) the 
one-compartment open model with constant rate intravenous infusion (Widmark and 
Tandberg, 1924). 
In the United States, Haggard, in the same year (1924), published his classical articles 
on the uptake, distribution and elimination of diethyl ether. He considered the distribu- 
tion of ether on theoretical grounds and also showed that the drug in brain approached 
equilibrium more rapidly than drug in the body as a whole and that this was the result of 
the high proportional blood flow to brain (Haggard, 1924a 1924e; Butler, 1964). These 
articles have always been considered a part of the basic physiology literature, but it is 
obvious that they deal with the subject matter of pharmacokinetics as well. Other contri- 
butions of physiologists in the United States in the early years included those of Moller 
et al., of Jolliffee and Smith who introduced the concept of renal clearance and of 
Hamilton et al. who reported on studies of the intravascular transport an indicator such 
as a dye (Moiler et al., 1929; Jolliffee and Smith, 1931; Hamilton et al., 1931). It was 
Hamilton et al. who introduced the following equations: 
V = tQ (1) 
f o  tC dt 
- (2) 
f o  C d t  
In Eqns (1) and (2), Vis the volume of the system, t is the mean transit time, Q is the 
blood flow, and C is the indicator concentration in plasma at time t. The numerator of 
the right-hand side of Eqn (2) is the area under the first moment of the concentration- 
time curve~ while the denominator is the area under the concentration-time curve. Equa- 
tion 2 has reappeared in pharmacokinetic articles published in 1978 and 1979 (Yamaoka 
et al., 1978, Benet and Galeazzi, 1979). 
In 1932, Widmark theorized that, following ingestion of ethyl alcohol and its equilibra- 
tion in body fluids, it disappears from the blood at a constant rate (zero-order elimin- 
ation) (Widmark, 1932). Much later, Lundquist and Wolthers and Wagner et al. showed 
that with moderate doses of alcohol, its elimination from human blood obeyed 
Michaelis-Menten kinetics and not zero-order kinetics (Lundquist and Wolthers, 1953; 
Wagner et al., 1976a). The reasons for the misinterpretation of Michaelis-Menten kin- 
etics as zero-order kinetics were discussed by Wagner (Wagner, 1973a). 
During the period 1939 to 1950, Dominquez in the United States made significant 
contributions with articles on the pharmacokinetics of creatinine, mannitol, xylose and 
galactose (Dominguez, 1934; Dominguez and Pomerene, 1934; Dominguez et al., 1935; 
Dominguez and Pomerene, 1944, 1945a,b; Dominguez et al., 1947a and 1947b; Dom- 
inguez, 1950). He introduced the concept of the volume of distribution and defined it as 
the hypothetical volume of body fluid dissolving the substance at the same concentration 
as that in plasma (Dominguez, 1934). Dominguez was also the first to derive and apply 
Eqn (3) to estimate the rate of absorption of a substance as a function of time. In Eqn (3), 
dA/dt  is the rate 
dA _ V dC 
at d / +  VkC (3) 
of absorption at time t, V is the volume of distribution, C is the plasma drug concen- 
tration at time t and k is the first-order elimination rate constant. 
In 1937, Teorell, a Swedish physiologist and biophysicist, published two remarkable 
articles which many now attribute as being the foundations of modern pharmacokinetics 
(Teorell, 1937a,b). The model of Teorell was one of the first physiologically-based 
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pharmacokinetic models. It comprised a five~compartment scheme representing the cir- 
culatory system, a drug depot, fluid volume, kidney elimination and tissue inactivation. 
Actual physiological volumes were used for the various regions of the model. For many 
years he was unaware that he had made significant contributions to what later came to 
be known as pharmacokinetics. However, at the Conference on Pharmacology and 
Pharmacokinetics, Problems and Perspectives held at the Fogerty International Center at 
the National Institutes of Health in Bethesda, Maryland, U.S.A. 1972, which he attended, 
Teorell's contributions were recognized. 
Bioavailability theory and testing has become an important topic in pharmacokinetics. 
Bioavailability is a term used to indicate the measurement of both the relative amount of 
an administered drug that reaches the general circulation intact and the rate at which 
this occurs. In the early years, bioavailability was called physiological availability. The 
concept was introduced by Oser and his associates in 1945, and their experimental work 
involved measurement of the bioavailability of vitamins administered in tablet form 
relative to their bioavailability administered in solution form (Oser et al., 1945, Melnick 
et al., 1945). 
The literature on the theory and application of isotopic (radioactive) tracers contri- 
buted much to compartmental modeling and this helped in the advance of pharmaco- 
kinetic theory. Here there were many contributors and I shall cite only some of the 
important articles (Solomon, 1949; Lax and Wrenshall, 1953, Reiner, 1953; Solomon, 
1953; Hart, 1955; Robertson, 1957; Russell, 1958; Cornfield et al., 1960; Shore, 1961). 
Lapp in France, in the period 1948-56, reported on a number of kinetic studies, 
principally involving excretion kinetics. Compounds he studied included salicylate, sto- 
varsol, uric acid, arsenic, sulfur, chlorine, sodium, rubiazol C, quinine, a soluble bismuth 
compound, sulfisoxazole and N'-acetylsulfisoxazole. He pointed out the application of 
kinetic data in therapeutics (Lapp, 1948, Lapp, 1949; Lapp, 1950a, Lapp, 1950b; Lapp 
and Speiser, 1950; Lapp and Lapp, 1952; Lapp, 1952; Lapp and Nicolay, 1954; Lapp and 
Scius, 1954; Lapp, 1956a; Lapp, 1956b). 
In 1948, Boxer and Jelinek in the United States considered the kinetics of the rise and 
fall of streptomycin blood concentrations with repeated dosage. They derived the equa- 
tions applicable to the maximum and minimum concentrations for the one-compartment 
open model with bolus intravenous injection when multiple doses are given at equal time 
intervals, but actually applied them to the case when streptomycin was administered 
intramuscularly (Boxer and Jelinek, 1948). During the next year, 1949, there were two 
other contributions from the United States. Goldstein published the first comprehensive 
review of the interaction between drugs and plasma proteins (Goldstein, 1949) and 
Gaudino published equations defining a two-compartment open model and applied them 
to inulin kinetics (Gaudino, 1949). 
The Dutch School made initial contributions in 1950 when DeJong and Wijans and 
Van Gemert and Duyff discussed the mathematical relationships between the dosage 
regimen and the pharmacological response. These appear to be the first articles con- 
cerned with optimization of dosage regimens of drugs (DeJong and Wijans, 1950; Van 
Gemert and Duyff, 1950). 
In 1951, Bray and his colleagues at the University of Birmingham in England, pub- 
lished the first of an extensive series of articles concerning the kinetics of formation of 
benzoic acid from benzamide, toluene, benzyl alcohol and benzaldehyde~ and its conjuga- 
tion with glycine and glucuronic acid (Bray et al., 195t~. 
In Germany, in 1953, Dost published the first edition of his book (Dost, 1953), dis- 
cussed in the beginning of this chapter. Der Bliitspiegel was an outstanding book for its 
time and fully covered the so-called one-compartment open model with its various forms 
of input. A revised edition of his book entitled Grundlagen der Pharmacokinetik was 
published in 1968. 
The year 1953, when Der Bliitspiegel was published, marks an appropriate termination 
of the section on the Origins of the Subject Matter of pharmacokinetics. The next reason- 
ably well-defined historical period appears to be from 1954 to 1961. During this period a 
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few, but not many, of the articles actually concerned with subject matter in the area of 
pharmacokinetics used the term pharmacokinet ics .  The year 1961 was chosen to end this 
second historical period, since, during that year, the English language reviews of Nelson 
(Nelson, 1961) and Wagner (Wagner, 1961) were published and considerable acceleration 
in interest in pharmacokinetics occurred from that time onwards. 
3. THE PERIOD 1954-1961 
In 1954 Butler et al. published an important article concerning elimination, accumu- 
lation, tolerance and dosage schedules of phenobarbital. This drug has a long elimination 
half-life, varying from about 2-6 days in man, and they showed that when administered 
once a day, accumulation was still occurring on the twelfth day. They also showed that 
plasma drug concentration, during a day at steady state, rises to a peak and falls to a 
trough, even when the half-life of a drug is long. Many investigators appear not to 
recognize that the term s teady-s ta te  concentrat ions does not mean constant or the same 
concentrations when drug is administered orally. When equal doses are administered at 
uniform time intervals the steady-state is characterized by the concentration, time profile 
reproducing itself between any two doses. If two or more doses are given each day at 
non-uniform time intervals (such as 0, 6 and 12hr), then the steady-state would be 
characterized by the concentration, time profile reproducing itself each day. 
Studies of the kinetics of elimination of glucose from blood during and after a continu- 
ous intravenous infusion (Jokipii and Turpeinen, 1954), and of the rate of absorption of 
water from the stomach and small bowel of human beings (Scholar and Code, 1954), are 
considered part of the classic literature of physiology but are also important in pharma- 
cokinetics. A parallel exists with an article concerning the volumes of distribution and 
clearance values of intravenously injected creatinine in the dog (Sapirstein et al., 1955). 
This study with creatinine is the first article where an intercompartmental clearance was 
mentioned and defined mathematically. Similarly, drug clearance (plasma clearance) was 
apparently first defined as the ratio of the intravenous dose to the area under the plasma 
concentration-time curve from zero to infinite time by Hoenig and Sch~ick (Hoenig and 
Schfick, 1956). Berman, who has made many important contributions to compartment 
model-building, made an early contribution with Schoenfeld (Berman and Schoenfeld, 
1956). The importance of the apparent elimination half-life of a drug in terminating its 
action was emphasized by Swintosky and co-workers and by Butler (Swintosky et al., 
1957; Butler, 1958). 
During this period Brodie, then at the Laboratory of Chemical Pharmacology, 
National Heart, Lung and Blood Institute, National Institutes of Health, published some 
of his classic pharmacology articles, which are important in pharmacokinetics. These 
were his articles on the gastric secretion of drugs (Shore et al., 1957) and on the kinetics 
of penetration of drugs and other foreign compounds into brain and cerebrospinal fluid 
(Mayer et al., 1957; Brodie et al., 1960). Riegelman, at the School of Pharmacy, Univer- 
sity of California, San Francisco, who has made many contributions to pharmaco- 
kinetics, initiated his publications in the area with an article on the kinetics of rectal drug 
absorption (Riegelman and Cromwell, 1958). One of the earliest articles showing a corre- 
lation between response and serum drug concentration reported a study of serum pheny- 
toin concentrations as a function of dosage, the time required to reach steady-state 
concentrations and a correlation between phenytoin serum concentrations and the 
degree of electroencephalographic abnormality in patients with epilepsy (Schiller and 
Buchthal, 1958). Although not a part of the pharmacokinetic literature, the publication 
by Williams of an extensive compilation on metabolism of drugs and other organic 
compounds, was an important milestone and the information that the book contained 
was useful in pharmacokinetic studies (Williams, 1959). 
Nelson, initially at the School of Pharmacy, University of California, San Francisco 
and later at the School of Pharmacy, State University of New York at Buffalo, made a 
number of important contributions to pharmacokinetics and biopharmaceutics. Prob- 
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ably the most important of these was his demonstration of dissolution rate-controlled 
absorption of drugs (Nelson, 1959; Nelson and Schaldemose, 1959). 
The concept that total body water could be divided into plasma, interstitial-lymph, 
dense connective tissue and cartilage, inaccessible bone water, transcellular and intra- 
cellular components later aided physiologically-based pharmacokinetic model-building 
(Edelman and Liebman, 1959). An elegant article on the pharmacokinetics of halothane 
anesthesia stimulated many studies on the uptake of halothane and other anesthetic 
agents (Duncan and Ravent6s, 1959). Duncan and Raventts reported that halothane in 
arterial blood reached steady state after about 1 hr of anesthesia, although the brain, liver 
and fat continued to take up the anesthetic for many hours. During the elimination of 
halothane, its arterial blood concentration decreased logarithmically with a half-life of 
14min. The venous blood concentration of halothane decreased rapidly at first, then 
followed its rate of decrease in the fatty tissues, with a half-life of 45 min. Other impor- 
tant contributions during this period were: (a) publication of a fundamental integral 
equation (Stephenson, 1960); (b) introduction of a curve-fitting method based on polyex- 
ponential equations (Perl, 1960); and (c) introduction of the use of the analog computer 
for fitting and simulating pharmacokinetic data and in model building (Garrett et al., 
1960; Wiegand and Taylor, 1960; Taylor and Wiegand, 1960). 
During this period and later, both Nelson and Kriiger-Thiemer attempted to consoli- 
date pharmacokinetics into a single scientific discipline. Kriiger-Thiemer, who worked 
for many years at the Forchungsinstitutes Borstel, Germany, was particularly interested 
in the theory and application of pharmacokinetics to dosage regimens of sulfonamides 
and antibiotics. He made a marked impression with his first English language paper 
concerning this subject (Kriiger-Thiemer, 1960a), subsequently publishing many other 
articles in both German and English (KriJger-Thiemer, 1960b; Kri,iger-Thiemer, 1961; 
KriJger-Thiemer and Schlender, 1963; Kriiger-Thiemer et al., 1966). 
During the late 1950's Brodie and associates elaborated the pH-partition hypothesis 
and discussed its application in the mechanism of absorption of drugs from the gastroin- 
testinal tract (Schanker, 1960). Other contributions during this period were (a) the work 
of Jenne et al. on the interpretation of isoniazid and p-aminosalicylic acid concentration- 
time curves (Jenne et al., 1960); (b) investigations of Wagner et al. with sustained release 
prednisolone formulations and their testing in the dog, in man and in vitro (Wagner et al., 
1960); (c) the development by Jacquez et al. of physiologically-based pharmacokinetic 
models (Jacquez et al., 1960); (d) studies by Onchi and Asao on the absorption, distribu- 
tion and elimination of diethyl ether in man (Onchi and Asao, 1961); (e) early work on 
the intestinal absorption of salicyclic acid by Japanese investigators (Nogami and Matsu- 
zawa, 1961); and (f) the first of many articles by Levy on salicylates (Levy et al., 1961). 
4. THE FIRST GROWTH PERIOD, 1961-1972 
Subsequent text will indicate the scope of pharmacokinetics as well as pointing out 
minor and major landmarks in development of the theory of pharmacokinetics, along 
with some applications. As with any similar review there will be inadvertent omissions 
and possibly misplaced emphasis, but the author sincerely tried to be fair to everyone 
who has contributed to pharmacokinetic theory. 
Biopharmaceutics may be defined as the study of the influence of formulation on the 
therapeutic activity of a drug product. It encompasses all possible effects of the dosage 
forms on biological response, and all possible physiologic factors which may affect the 
drug contained in the dosage form and the dosage form of the drug itself (Wagner, 1971). 
In 1961 the author published a review article entitled: Biopharmaceutics: Absorption 
Aspects which caught the eye of many pharmaceutical and other scientists (Wagner, 
1961). This review, along with that of Nelson (Nelson, 1961), resulted in a marked rise in 
interest in pharmacokinetics. During this period, a number of books in the area of 
pharmacokinetics appeared. These are listed in Table 1. 
In 1962, Pharmakokinetik und Arzniemitteldosierung, the first symposium with a title 
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TABLE 1. Books Dealing with Pharmacokinetic Principles Published between 1961-1972 
The Mathematical Approach to Physiological Problems (Riggs, 1963) 
Uptake and Distribution of Anesthetic Agents (Papper and Kitz, 1963) 
Pharmacogenetics (Kalow, 1965) 
Drug and Tracer Kinetics (Rescigno and Segr6, 1966) 
Grundlagen der Pharmacokinetik (Dost, 1968) 
Multicompartment Models for Biological Systems (Atkins, 1969) 
Biopharmaceutics and Relevant Pharmacokinetics (Wagner, 1971a) 
Biopharmaceutics and Pharmacokinetics: An Introduction (Notari, 1971) 
Guidelines for Biopharmaceutical Studies in Man (Dittert et aL, 1972) 
Schering Workshop on Pharmacokinetics (Rasp6, 1970) 
Tracer Methods for In Vivo Kinetics: Theory and Applications (Shipley and Clark, 1972) 
incorporating the term pharmacokinetics, was held in Borstel, Germany. The proceed- 
ings of this symposium were subsequently published in volume 12 of Antibiotica and 
Chemotherapia. The book and the symposium were potent forces in disseminating 
pharmacokinetic knowledge. 
Publishing in the endocrinology area in 1963, Tait wrote a clear exposition of the 
meaning of clearance (metabolic clearance rate) and its relationship to hepatic blood 
flow, as well as the effect of postural changes on effective hepatic blood flow (Tait, 1963). 
It was not until ten years later that Rowland et al. made significantly greater use of the 
clearance concept (Rowland et al., 1973). 
A method of estimating the amount of drug absorbed per milliliter of the volume of 
distribution versus time from either blood (serum or plasma) concentration-time data or 
urinary excretion data, based upon the one-compartment open model, later came to be 
known as the Wagner-Nelson method (Wagner and Nelson, 1963). An analogous 
method, based on the two-compartment open model, was later called the Loo-Riegelman 
method (Loo and Riegelman, 1968). 
The representation of certain mammillary N-pool systems by two-pool models was the 
subject of an interesting article published in 1964 (Shaney et al., 1964). The problem of 
vanishing exponential terms in polyexponential equations was again treated considerably 
later (Wagner, 1976a; Ronfeld and Benet, 1977). These theoretical articles suggested that, 
if a panel of subjects were administered the same dose of drug by the same route of 
administration and the resulting blood (serum or plasma) concentration-time data were 
fitted by polyexponential equations with the statistically optimum number of terms per 
data set, different subjects would require different numbers of terms. Experimental verifi- 
cation of this prediction came with the data of Kalow and co-workers (Endrenyi et al., 
1976). They administered an intravenous dose of 125 mg of sodium amobarbital to seven 
pairs of identical twins and to seven pairs of fraternal twins. Blood samples were taken at 
uniform intervals and plasma was analyzed for amobarbital by a GLC method. Concen- 
tration-time data were fitted via a nonlinear estimation program and a digital computer 
to polyexponential equations where the optimum number of terms was decided by a 
statistical F-test. Results are shown in Table 2. These results may be attributed to the 
relative magnitudes of the coefficients and exponents characterizing the curves of the 
TABLE 2. Results of  Computer Fitting Amobarbital Plasma Con- 
centration-Time Data (Endryi et al., 1976) 
Optimum number of Percentage of 
exponential terms Number of subjects subjects 
1 5* 18 
2 16 57 
3 7 25 
Total 28 100 
*One of these 5 subjects gave only one exponential term on 
each of three different occasions. 
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various subjects. The authors stated: 'Variability in the number of detectable exponential 
terms (emphasis being given to the word 'detectable') does not necessarily imply that, in 
different subjects, the disposition of amobarbital is characterized by differing numbers of 
compartments.' The author of this chapter now thinks it is much preferred to speak or 
write about monoexponential, biexponential and triexponential equations rather than 
one, two or three compartment open models. 
Several reviews were published during this period. One covered the stimulatory effect 
of chronic drug administration on drug-metabolizing enzymes in liver microsomes 
(Burns et al., 1963)--which has implications in pharmacokinetics. Another dealt with the 
pharmacokinetics of halothane and ether (Butler, 1964). The third was titled Pharmaco- 
kinetics and was the first time this topic was covered in Annual Reviews of  Pharmacology 
(Wagner, 1968b). In this period, an interest in pharmacokinetic drug interactions began 
with the report of the effect of phenobarbital on lowering plasma concentrations of both 
bishydroxycoumarin and phenytoin (Cucinell et al., 1965). 
Beckett and Rowland related diurnal urine pH variations with pH-dependent renal 
clearance of a drug. This article led to a large body of research which had implications in 
therapy, in drug product evaluation using urinary excretion data, in basic research, and 
in tests for 'doping' in sport (Beckett and Rowland, 1965). 
The articles of Levy (Levy and Nelson, 1965; Levy, 1966; Levy et al., 1969; Nagashima 
et al., 1969) considered the kinetics of pharmacologic response and brought into focus 
relationships between intensity and duration of a pharmacologic response and the 
plasma drug concentration. 
The simultaneous fitting of blood norepinephrine-time data and blood pressure-time 
data by Segr6 was also an advance in this important area of pharmacokinetics (Segr6 
1968). A logarithmic-logistic equation was also suggested to relate intensity of response 
to blood concentrations (Wagner, 1968a). 
In 1965 Wagner et al. published a simple equation to estimate time-average steady 
state (blood, serum, or plasma) concentrations, Car, from the availability factor, F, the 
dose, D, given every z hr, the volume of distribution, V, and the apparent elimination rate 
constant, k, as shown in Eqn (4). At the time of its publication this equation was 
referenced to the one-compartment open model. Gibaldi and Weintraub later showed 
that in multicompartment systems Eqn (4) could be written as Eqn (5) where 2z is the 
terminal exponential coefficient and the product VAz is the clearance (Gibaldi and Wein- 
traub, 1971). Still later Perrier 
FD 
C.v = Vkz (4) 
FD 
C,v = - -  (5) 
V2zr 
and Gibaldi showed that one must multiply both sides of Eqn (5) by the volume of 
distribution steady state, Vs,, to obtain the amount of drug in the body for a multicom- 
partmental system (Perrier and Gibaldi, 1973). 
It was during this period that pharmacokinetic articles which had a considerable 
impact on therapeutics began to appear and clinical pharmacokinetics was really 'born'. 
Noteworthy were the articles of Dettli on drug accumulation and dosage in patients with 
impaired renal function (Dettli et al., 1967; Dettli, 1970); of Jelliffe on digoxin dosage 
(Jeliffe, 1968); of Orme and Cutler who correlated kanamycin clearance with creatinine 
and inulin clearances (Orme and Cutler, 1969; Cutler and Orme, 1969); of Nagashima et 
al. on the anticoagulant action of warfarin (Nagashima et al., 1969); and that of Levy on 
the non-linear elimination kinetics of salicylate (Levy et al., 1972). 
It was also during this period that Garrett further illustrated the usefulness of the 
analog computer (Garrett and Lambert, 1966) and Berman published details of his 
nonlinear estimation program, called SAAM, to be used in model-building with large 
digital computers (Berman and Weiss, 1966). 
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The mathematics of the rate of drug accumulation in the one-compartment open linear 
system was apparently first considered in 1968 (Wagner and Northam, 1968: Van Ros- 
sum, 1968). A year later, exact solutions were given for the number of doses required to 
reach various percentages of the steady state value for the one and two-compartment 
open model with first-order absorption (Wagner and Northam, 1968: Wagner, 1969). 
Physiologically-based models were introduced to describe the handling of drugs by the 
artificial kidney (Dedrick and Bischoff, 1968), as well as the pharmacokinetics of thiopen- 
tal (Bischoff and Dedrick, 1968) and methotrexate Bischoff et al., 1971). 
The years 1967-1969 also provided many theoretical articles which later became part 
of classical pharmacokinetics. These articles included: (a) a new method of estimating 
drug bioavailability (Wagner, 1967); (b) shortcomings in pharmacokinetic analysis by 
conceiving the body to exhibit properties of a single compartment (Riegelman et al., 
1968a); (c) the relationship between drug concentration and amount of drug in the body 
(Gibaldi et al., 1969); (d) the influence of route of administration on the area under the 
plasma concentration-time curve (Harris and Riegelman, 1969: Gibaldi and Feldman, 
1969); (e) the effect of mode of administration on drug distribution in a two-compartment 
open system (Gibaldi, 1969); (f) volume terms in pharmacokinetics (Ronfeld and Benet, 
1969) and (g) an analysis pointing out that the displacement of drugs from plasma 
proteins would have only a trivial effect on the plasma concentration of unbound drug, 
when the binding was less than 90~ (Gillette, 1968). Also, in 1969, Metzler introduced 
the nonlinear digital computer program called NONLIN, which subsequently became 
very widely used (Metzler, 1969). 
It is simplistic to interpret apparently multiexponential concentration-time curves on 
the basis of linear compartment models. Plasma protein binding and/or tissue binding of 
drugs are often nonlinear processes. During 1971, several authors discussed the impli- 
cations of such nonlinear binding and some developed useful models (Gillette. 1971: 
Coffey et al., 1971; DiSanto, 1971; Wagner, 1971), During the same year, Smolen pub- 
lished a series of articles on assessment of drug absorption using pharmacological data 
(Smolen and Schoenwald, 1971; Smolen, 1971). 
Suzuki et al. (Suzuki et al., 1970a,b) and Ho and Higuchi (Ho and Higuchi, 1971) 
discussed multicompartment diffusional models for the absorption of neutral, acidic, 
basic and and amphoteric drugs and applied the theory to the buccal absorption of 
n-alkanoic acids. These were the first in a long series of articles employing these models. 
At the end of this period, namely 1972, Benet published the first general treatment of 
linear mammillary models (Benet, 1972). This was followed later by general treatments by 
other authors (Vaughan and Trainer, 1975; Pedersen, 1978). 
5. THE SECOND GROWTH PERIOD, 1973 1979 
5.1. LITERATURE 
During this period pharmacokinetic literature grew at a very rapid rate. By the end of 
1972 there were several journals which published pharmacokinetic articles. Examples of 
these are: Journal of Pharmaceutical Sciences; European Journal of Clinical Pharmacoloyy 
(from Vol. 3, No. l, December 1970 to date; formerly Pharmacologia Clinica); Inter- 
national Journal of Clinical Pharmacology and Biopharmacy (formerly International Jour- 
nal of Clinical Pharmacology, Therapy and Toxicology); Clinical Pharmacolooy and 
Therapeutics; and Journal of Clinical Pharmacology. 
During 1973-1979 these journals continued to publish their share of pharmacokinetic 
articles, and, in some cases, the number increased each year. For example, in Clinical 
Pharmacology and Therapeutics, the numbers of articles published, which dealt with 
aspects of pharmacokinetics, were 43 in 1973, 63 in 1974, 88 in 1975 and over 100 in 
1976. 
However, many of those publishing articles in the pharmacokinetic area desired their 
own forum, hence speciality journals were established. The three most important of these 
History of pharmacokinetics 545 
are: Journal of  Pharmacokinetics and Biopharmaceutics, Vol. l, No. 1, published in Febru- 
ary, 1973; Clinical Pharmacokinetics, Vol. 1, No. 1, published in January, 1976; and 
Biopharmaceutics and Drug Disposition, Vol. 1, No. l, published in July-September, 1979. 
Some other journals established during the same years, namely European Journal of  Drug 
Metabolism and Pharmacokinetics, International Journal of  Pharmaceutics and Therapeu- 
tic Drug Monitoring, also published many articles in pharmacokinetics. 
Clinical Pharmacokinetics contains, in addition to mainly review articles and some 
original articles, a list of Current References in Clinical Pharmacokinetics. This section 
contained 465, 503 and 448 references for the years 1976, 1977 and 1978, respectively. 
During this period many books were published (Table 3). 
5.2 MODELS 
Models for elimination by the intact liver. As far back as 1963, Tait, in a review on the 
use of isotopically labelled steroids, stated: 'the metabolic clearance rate can be con- 
sidered to be the blood flow through a hypothetic organ which completely and exclus- 
ively extracts the steroid' (Tait, 1963). He also gave examples where hepatic clearances of 
hormones were decreased both by change from the recumbent to the upright body 
position and by disease states, such as cirrhosis and congestive heart failure. 
Two types of well-defined quantitative models have been developed which attempt to 
describe the elimination of substrates from the intact liver. One of these models has been 
called the well-stirred model (Pang and Rowland, 1977a,b,c) or the venous equilibration 
model (Bass, 1979). It was primarily developed by Rowland (Rowland et al., 1973) but 
many others have made significant contributions (Gibaldi and Feldman, 1969; Gibaldi et 
al., 1971 ; Perrier and Gibaldi, 1972; Perrier et al., 1973a; Evans et al., 1973; Shand et al., 
1973, 1975 and 1976; Branch et al., 1973; Branch and Shand, 1976; Wilkinson, 1975; 
Wilkinson and Shand, 1975; Wilkinson and Schenker, 1976, Pang and Rowland, 
1977a,b,c; McLean et al., 1978; Kornhauser et al., 1978). The other model has been called 
the parallel tube model (Pang and Rowland, 1977a) as well as the sinusoidal perfusion 
model (Bass, 1979). In quantitative terms this model has been stated most clearly by Bass 
et al. (Bass et al., 1976; 1977; 1978; Bracken and Bass, 1979), but several others have been 
involved in its evolution (Goresky and Bach, 1970; Winkler et al., 1973; Goresky et al., 
1973; Winkler et al., 1974; Keiding et al., 1976; Keiding, 1976; Keiding and Chiarantini, 
TABLE 3. Books Dealing with Pharmacokinetic Principles Published between 1973 1979 
Drug Dosage Form Design and Bioavailability (Swarbrick. 1973) 
Pharmacokinetik (Gladtke and von Huttingberg, 1973) 
Clinical Pharmacokinetics, A Symposium (Levy, 1974a) 
Basics of Bioavailability and Description of Upjohn Single Dose Study Design (Chodos and DiSanto, 1974) 
Anesthetic Uptake and Action (Eger, 1974) 
Manual de Iniciacion a la Biofarmacia (Farmacocinetica Aplicado) (Pl~i Delfina and Pozo Ojeda, 1974) 
Pharmacology and Pharmacokinetics (Teorell et al., 1974) 
Fundamentals of Clinical Pharmacokinetics (Wagner, 1975a) 
Drug Disposition and Pharmacokinetics with a Consideration of Pharmacological and Clinical Relationships 
(Curry, 1974) 
Biopharmaceutics and Pharmacokinetics. An Introduction, Second Edition (Notari, 1975) 
Pharmacokinetics (Gibaldi and Perrier, 1975) 
The Effect of Disease States on Drug Pharmacokinetics (Benet, 1976) 
Pharmacokinetics of Psychoactive Drugs: Blood Levels and Clinical Response (Gottschalk and Merlis, 1976) 
Biopharmaceutics and Clinical Pharmacokinetics (Gibaldi, 1977) 
Industrial Bioavailability and Pharmacokinetics Guidelines, Regulations, and Controls (Martin and Doluisio. 
1977) 
Drug Disposition and Pharmacokinetics, Second Edition (Curry, 1977) 
Clinical Pharmacokinetics: Proceedings of an International Symposium at Salzgitter-Ringelheim (Ritschel, 
1977) 
Pharmacokinetics (Sch6feld, 1978) 
Pharmacokinetics, An Introduction (Gladtke, 1979) 
Textbook of Biopharmaceutics and Clinical Pharmacokinetics (Niazi. 1979) 
Drug Disposition in Humans. The Basis of Clinical Pharmacology (Creasey, 1979) 
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1978; Bass and Robinson, 1979). This last model has both a primitive undistributed form 
as well as a distributed form (Bass, 1979). The well-stirred model describes the liver as a 
well-stirred compartment with the drug in the hepatic venous blood being in equilibrium 
with that in the liver. The parallel tube model regards the liver as a series of parallel tubes 
with enzymes distributed evenly around the tubes and the concentration of drug declines 
along the length of each tube. One article of Bass gets to the crux of the difference 
between the two theories (Bass, 1979). There are experimental data supporting both 
models, and some experimental data that are not adequately explained by either theory 
(Pang and Gillette, 1978). The analogy between the perfusion-limited isolated organ 
system and the two-compartment open model with elimination from the peripheral 
compartment provided a physiological basis for classical pharmacokinetic compartment 
models (Rowland et al., 1973). The articles cited in this section also clarify that the 
determinants of hepatic clearance are liver blood flow, the activity of drug metabolizing 
enzymes and the binding of drug in blood to serum proteins and cellular elements. 
From the experimental findings and theoretical considerations, a number of very useful 
equations were derived which relate such variables as total area under the blood concen- 
tration-time curve (AUC), the intravenous dose (D) or oral dose (Dpo), clearance of drug 
(CL), availability (F), extraction ratio (E) and effective liver blood flow (Q). For a drug 
which is exclusively eliminated by liver metabolism and completely absorbed, a novel 
way to write one of these relationships is shown as Eqns (6) and (7) where CLn is the 
hepatic clearance, CLn/F is the intrinsic hepatic clearance, F = 1 - E and Vmax, i and 
K,.,i are the maximum velocities and Michaelis constants for the various 
1 
CLn = (6) 
1 1 
Q (CLn/F) 
CLn_  ~ Vm~,i 
F , : ,  Km,'i (7) 
biotransformation reactions occurring in the liver. One can see from Eqn (6) that when 
intrinsic hepatic clearance is small relative to blood flow then 
1 1 
O_ 
and hepatic drug clearance is controlled by the metabolism reaction(s) and is essentially 
independent of liver blood flow. Conversely, when intrinsic hepatic clearance is large 
relative to blood flow, then hepatic drug clearance approaches hepatic blood flow. When 
intrinsic hepatic clearance is usually assigned a new symbol such as  CLin t rather than 
writing it as CLn/F or CLn/(1 - E); this can get one into trouble since one might not 
realize when the variable CLn is separated or not. 
General treatment of linear mammillary models. As indicated above, Benet published 
methods to obtain the integrated expressions for the amount of drug in the central 
(compartment no. 1) or in any peripheral compartment of an n-compartment mammil- 
lary model, where elimination could occur from any one or more compartments, but 
where input was always into the central compartment only (Benet, !972b). Vaughan and 
Trainor later derived a general disposition equation for a linear mammillary model with 
n-compartments, and used it to define disposition equations for the central compartment 
when drug input takes place into the central or into a peripheral compartment. Equa- 
tions describing the entire time-course of drug in a particular compartment after intra- 
venous, intramuscular, oral and rectal drug administration were presented (Vaughan and 
Trainor, 1975). Pederson later published another general treatment for input into one or 
more compartments and elimination from one or more compartments. Two approaches 
were described: one based on a full Laplace transformation and one that avoids trans- 
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formation of the input function(s) and the use of convolution integrals. The latter 
approach is important when dealing with complex input functions not having a simple 
Laplace transform (Pederson, 1978). 
Cancer chemotherapy models. Jusko proposed a pharmacodynamic model for the quan- 
titative analysis of dose-time-cell survival curves produced by the administration of 
cell-cycle-specific chemotherapeutic agents (Jusko, 1973). Himmelstein and Bischoff de- 
veloped predictive models to simulate cancer cell populations under treatment with 
cytotoxic drugs, with both direct-acting and cell-cycle-specific drugs. Models of cell 
growth kinetics were combined with simple pharmacokinetic models to complete the 
cell-drug interaction system (Himmelstein and Bischoff, 1973a). These models were 
applied to the treatment of L1210 leukemia in mice with ARA-C (1-fl-D-arabinofurano- 
sylcytosine) and the results of various treatment schedules were simulated; the simulated 
data agreed quite well with experimental data (Himmelstein and Bischoff, 1973b). Physio- 
logically-based pharmacokinetic models for anticancer drugs were reviewed by Chen and 
Gross (Chen and Gross, 1979a). 
Other physiologically-based pharmacokinetic models. The physiological pharmacokinetic 
approach to the modeling of drug distribution was reviewed (Himmelstein and Lutz, 
1979). One advantage of such modeling is that it allows extrapolation outside the range 
of data, with some confidence, if the dominant mechanisms of transport are sufficiently 
well understood. Another advantage is that one may scale from a species of one size to 
that of a larger or smaller size. The compartments of such models correspond to anato- 
mical spaces so that biochemical interactions, including drug effects or pharmacodyna- 
mics, may be incorporated in the model. 
Two experimental methods are important with respect to these models. Rane et al. 
described a method to predict intrinsic clearance for an in vivo model from enzyme 
kinetic data obtained in vitro. They reported a remarkably good correlation between 
hepatic clearance predicted by the method and the clearance observed in isolated liver 
preparations. The method, in effect, utilizes Eqn (7) above (Rane et al., 1977). Important 
parameters in the development of physiologically-based models are the tissue-to-plasma 
partition coefficients. The estimation of these parameters have been discussed in detail 
(Chen and Gross, 1979b), 
Stochastic models. Several articles dealing with stochastic theory of one- and two- 
compartment systems (Purdue, 1974), as well as the solution for an n-compartment 
system with irreversible time-dependent transition probabilities (Cardenas and Matis, 
1974), have appeared. In addition, a general time-independent stochastic model was 
described (Faddy, 1976). Vaughan and Hope discussed applications and advantages of a 
recirculatory stochastic pharmacokinetic model for representing drug distribution and 
elimination (Vaughan and Hope, 1979). 
Linear plasma protein and tissue binding. Levy and Yacobi showed that the total 
plasma clearance of the highly plasma protein bound drug, warfarin, in rats was a linear 
function of the free (unbound) fraction of drug in plasma (Levy and Yacobi, 1974b; 
Yacobi and Levy, 1975 and 1977). 
Gillette has published articles which illustrate the importance of linear plasma protein 
and tissue binding in drug disposition (Gillette, 1971 and 1973; Gillette and Pang, 1977) 
and the literature on such binding has been well reviewed (Wagner, 1973b; Jusko and 
Gretch, 1976). Simple pharmacokinetic models incorporating linear plasma protein bind- 
ing, linear tissue binding and first-order elimination of free (unbound) drug were studied 
intensively (Wagner, 1976b; Gibaldi and McNamara, 1978). 
Based on an equation of Gillette (Gillette, 1971), Wilkinson and Shand proposed that 
Eqn (8) would apply, where V is the apparent volume of distribution of a drug with 
respect to the total systemic venous drug concentration, VB represents the blood volume, 
Vr represents the volume of 
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other tissues of the body into which the drug distributes and fur  and Jub are the fractions 
of drug present in the unbound form in the tissue and blood, respectively (Wilkinson and 
Shand, 1975). Gibaldi and McNamara showed a derivation of an equation with the same 
form as Eqn (8), but the symbols were defined as follows: VB is the plasma volume, VT is 
the difference between the volumes of total body water and plasma, and fuT is the 
fraction of drug unbound in tissue (i.e. the weighted average fraction of free drug in 
extraplasma space) and V is the steady-state volume of distribution (Gibaldi and 
McNamara, 1978). This is a considerably different interpretation of the equation. The 
latter equation was then used to derive some other relationships concerning the effect of 
plasma protein and tissue binding on the biologic half-life of drugs (Gibaldi et al., 1978). 
However, Oie and Tozer pointed out that the interpretation of Gibaldi and McNamara 
did not take into account that plasma proteins are also distributed throughout the 
extracellular fluids. They derived a much more complicated expression for the volume of 
distribution of a drug (Oie and Tozer, 1979). 
Nonlinear pharmacokinetics and models. Evidence of nonlinearities in pharmacokinetic 
data goes back to the early 1930's, with the origination of the concept that ethyl alcohol 
is sometimes eliminated at a fixed rate, independent of its concentration in the body. The 
author's review article (Wagner, 1973b), contained references to over 160 articles which 
suggest evidence of nonlinearities in drug absorption, distribution, metabolism and excre- 
tion and the pharmacokinetics of drug action. A later review also presented extensive 
evidence of nonlinearities (Jusko and Gretch, 1976). Nonlinear elimination kinetics will 
be considered first, followed by nonlinear plasma protein and tissue binding. 
By means of theoretical considerations and simulations it was shown that an apparent 
increase in the biological half-life of a drug with increasing dose could result from 
product inhibition if the dissociation constant for the drug metabolite-enzyme complex 
is appreciably lower than the Michaelis constant for the drug-enzyme complex, if drug 
metabolite concentrations remain relatively constant for some time as a result of slow 
elimination of the metabolite, and if the level of drug in the body does not appreciably 
exceed the apparent in vivo Michaelis constant (Perrier et al., 1973b). A theory which 
explains phenomena exhibited by pooled nonlinear pharmacokinetic systems and equa- 
tions relating pooled Michaelis-Menten constants Vmp, Kmp, to microscopic constants 
Vmi, Kmi was presented (Sedman and Wagner, 1974). A model, based on physiologic 
considerations, was shown to describe the entire time course of blood alcohol concen- 
trations after four different doses of alcohol administered orally (Wilkinson et al., 1977). 
If elimination obeys Michaelis-Menten kinetics, the rate of accumulation depends not 
only on the magnitudes of the maximal velocity and Michaelis constant but also on the 
rate of drug input to the body. Simulations of the time course of drug accumulation were 
carried out for phenytoin--a drug whose elimination obeys Michaelis-Menten kinetics 
(Wagner, 1978; Ludden et al., 1978; Lam and Chiou, 1979). These theoretical predictions 
were supported by the measurement of phenytoin serum concentrations (Allen et al., 
1979). 
Kunka and Mattocks showed that one of the nonlinear models of DiSanto (1971) and 
Wagner (1971b) adequately described the pharmacokinetics of acetazolamide in the rab- 
bit (Kunka and Mattocks, 1979). The model employed involved two saturable tissue 
binding sites and first-order elimination of free (unbound) drug. Extraction of proprano- 
lol by the perfused rat liver was shown to be dose-dependent (Evans et al., 1973). This 
article, by Evans et al., is unique in that it is the only work with physiologically-based 
modeling in which the parameters were simultaneously and statistically best fitted to the 
data. The pharmacokinetic analysis provided new insight into the biology of the system 
which was not apparent from the raw data, or from any simple manipulation thereof. 
The clinical importance of the nonlinear plasma protein binding of disopyramide was 
emphasized. In the 12 patients ~tudied, at any given total disopyramide plasma concen- 
tration, there was approximately a twofold range in the fraction of disopyramide 
unbound to plasma proteins. Hence mean plasma protein binding data or data on 
protein binding obtained from pooled plasma are of little value in a given patient, for 
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predicting unbound disopyramide concentrations from measurements of total disopyra- 
mide concentrations (Meffin et al., 1979). 
Simulation of plasma drug concentration-time profiles for a number of systems incor- 
porating nonlinear plasma protein and/or tissue binding were reported. For the extensive 
conclusions the original articles should be consulted (McNamara et al., 1979a,b). One of 
the conclusions of this work was that for nonlinear plasma protein and/or tissue binding 
models there will always be a pronounced '~-' or 'distribution' phase after cessation of an 
infusion for any length of time, whereas in a linear pharmacokinetic system the 'ct-' or 
'distribution' phase tends to disappear the longer is the infusion time. However, in linear 
systems it is not only the infusion time but also the value of the ratio C221/C~)t 2 which 
determines the degree of disappearance of the ~t-phase (Kampman, 1979); here C1 and 21 
are the coefficient and the exponential coefficient respectively, of the first term and C2 
and 22 are the coefficient and exponential coefficient of the second term of the biexpo- 
nential equation for a linear system after bolus intravenous administration. 
How the area-dose and area-initial plasma concentration relationships may be used to 
study nonlinear processes was explored and a general theorem proven. Assuming 
Michaelis-Menten elimination kinetics and Langmuir type tissue binding, several area- 
dose and area-initial plasma concentration relationships were derived (Chau, 1976). 
Miscellaneous. Pharmacokinetic models and the basic concepts involved in applying 
models to blood, urine, bile and tissue levels of drugs and metabolites were reviewed 
(Garrett, 1973). The principle of area analysis was used in the development of a metabolic 
and pharmacokinetic model for an extensively biotransformed drug, N4-ethoxyacetyl- 
sulfamethoxazole in the monkey (Kaplan et al., 1973). The first attempt to define quanti- 
tatively by radioautography the rate and extent of metabolism of a cephalosporin anti- 
biotic in animals and man was made by Cabana et al. They also established, by renal and 
metabolic clearance measurements, the definite role of the kidney in drug metabolism. 
Their studies demonstrated that the renal clearance of desacetylcephapirin, an active 
metabolite of cephapirin, was not proportional to its plasma concentration and that the 
clearance far exceeded renal plasma flow (Cabana et al., 1975). Niazi defined a volume of 
distribution as a function of time for a multicompartment model; it equals the usual 
value, based on area considerations, in the log-linear phase of plasma concentration-time 
data (Niazi, 1976). A linear recirculation model for drug disposition in which disposition 
is regarded as the result of repetitive passes of the drug around the circulation was 
described (Cutler, 1979). A new definition of a compartment in pharmacokinetic model- 
ing was published (Cutler, 1978a). 
5.3. MODEL-INDEPENDENT METHODS 
The convolution integral of Stephenson (Stephenson, 1960) is useful in linear systems 
analysis (Cutler, 1978b). Numerical deconvolution methods were described and illus- 
trated by several authors (Rescigno and Segr6, 1966; Benet and Chiang, 1972a; Wagner, 
1975b; Cutler, 1978c,d). 
Dost's law of corresponding areas was stated as: 'the ratio of the area beneath the 
blood level-time curves, after oral administration to that following intravenous adminis- 
tration of the same dose, is a measure of the absorption of the drug administered' (Dost, 
1968). When 'absorption' is equated with 'efficiency of absorption' both Niiesch (NiJesch, 
1973) and Vaughan (Vaughan, 1977) offered proofs of Dost's law. However, a drug may 
be completely absorbed but only a fraction of the dose reach the circulation intact as a 
result of the 'first pass' effect. Hence, Wagner suggested that Dost's law of corresponding 
areas be replaced by Eqn (9), where F is the fraction of the dose, Dpo, which is absorbed 
(0 <_ F _< 1), F* is the bioavailability 
,9, 
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factor due to the first-pass effect (0 < F* < 1), D and Dp0 are the intravenous and oral 
doses, respectively, and the integrals are the total areas under the concentration-time 
curves following oral and intravenous administration, respectively. He also showed that 
for some modeJs F* = 1 and for others F* ¢ 1 (Wagner, t976c). In the real world we 
also know that drugs with high hepatic clearances have a significant liver 'first-pass' effect 
and that other drugs are metabolized as they pass through the gut wall, which also would 
make F* less than unity. Dost also extended his method to obtain an absorption profile 
of the drug via a graphical procedure, which was shown by Galeazzi and Benet to be the 
graphical equivalent of the Wagner-Nelson method (Galeazzi and Benet, 1976; Wagner 
and Nelson, 1963). Still later Dost (Dost, 1970a,b) extended his graphical procedure 
to multicompartment systems, but this was shown to be inappropriate (Galeazzi and 
Benet, 1976). 
Some model-independent prediction methods for use in pharmacokinetics were dis- 
cussed by Amidon et al. (Amidon et al., 1975). One of these was a method to estimate the 
asymptote of a curve when the values of the function are approaching the asymptote 
according to first-order kinetics (monoexponential function). Their method employed 
three concentration-time points and was extended to any number of points (Wagner and 
Ayres, 1977). These methods are most useful for estimating the area under a concentra- 
tion-time curve from zero to infinite time or the cumulative amount of a drug excreted in 
the urine in infinite time after a single dose of drug. The method was later extended to 
biexponential processes (Newburger et al., 1979). 
An important parameter in pharmacokinetics is the volume of distribution steady 
state, which has had an interesting history. If the kinetics are linear then the time course 
of the plasma drug concentration, C, following a single i.v. bolus dose will be given by 
Eqn (10). The volume of distribution steady state, V~, is then given by Eqn (11), 
C = ~ Ci e - j ' '  (10) 
i=1 
where Aeq and Ceq are respectively the amount of drug in the body and the plasma 
drug concentration at equilibrium (i.e. the instant in time when the rate of change 
of drug in the one or more peripheral compartments of the n-compartment mammillary 
model is equal to zero), k12 , k21 . . . .  kt,, k,,~ are the forward 
- = . . . . .  ~= 1 _ - t C L  
L [ [fo ] Ce q I + k:~ + + k . d  Vt C~ ~ C~/2~ C dt i=1 
(11) 
and reverse first-order rate constants between the peripheral compartments and the 
central compartment, V I is the volume of the central compartment, ,4, and Cs~ are the 
average amount of drug and concentration, respectively, at steady state in the n-compart- 
ment mammiilary model with elimination from the central compartment only, D is the 
dose after bolus intravenous injection, t is the mean residence time [see Eqn (2)] and C L  
is the mean drug clearance. Riggs first defined V~s for the two-compartment open mam- 
millary model with elimination from the central compartment only (i.e. n = 2), using the 
second and third equalities of Eqn (11) (Riggs, 1963). V~ and other 'volumes of distribu- 
tion" were discussed later (Riegelman et al., 1968b). A volume of distribution was defined 
by the equivalent of the fifth equality of Eqn (1) in a footnote of a table in a chapter by 
van Rossum (van Rossum, 1971). The derivation of the fifth equality of Eqn (11), based 
or, the fourth equality was given by Wagner (Wagner, 1976d). Oppenheimer et al. 
(Oppenheimer et al., 1975) defined a noncompartmental volume of distribution with the 
sixth and seventh equalities of Eqn (11). Benet and Galeazzi clarified that this noncom- 
partmental volume of distribution was equivalent to the V,, which had been used for 
many years, and that the integrals in the sixth equality of Eqn (11) could be estimated 
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directly from C, t data without use of a model at all (Benet and Galeazzi, 1979). Hence a 
volume that was originally defined very restrictively has evolved into a model-indepen- 
dent term. 
5.4. OPTIMAL INPUT CALCULATIONS 
A safe method for rapidly achieving plasma concentration plateaus (i.e. steady-state 
concentrations) based on the two-compartment open model and involving two consecu- 
tive infusion rates was reported (Wagner, 1974). Later a general derivation was made and 
applied to steady-state concentrations of lignocaine (Vaughan and Tucker, 1976). In 
addition, a general method was described for computing drug regimens which are opti- 
mal in the sense of minimizing the sum of squared deviations of the predicted drug 
concentration in a compartment from a desired concentration in that compartment 
(Wheeler and Sheiner, 1976). 
5.5. COMPUTERS AND STATISTICAL ANALYSIS 
Several important statistical aspects of pharmacokinetic analysis were discussed (Box- 
enbaum et  al., 1974). These included selection of appropriate equations, weighting of 
data, precision of parameter estimates, analysis of weighted residuals, and criteria useful 
in selection of the final model. Colburn et  al. published a digital computer program 
which utilizes the nonlinear least squares regression program NONLIN (Metzler, 1969) 
to fit particular models to concentration-time data when the data are collected during 
repetitive dosing of the drug (Colburn et  al., 1976). Sheiner et  al. described a method of 
estimating population characteristics of pharmacokinetic parameters from routine clini- 
cal data (Sheiner et  al., 1977). Several drug concentration values from each individual, 
along with dosage information and the results of other routinely assessed variables suffice 
for purposes of analysis. The generality and appropriateness of the analytic technique 
were demonstrated by analysis of a set of data derived from 141 patients who were 
receiving digoxin. The usefulness of statistical moments of concentration-time data was 
emphasized (Yamaoka et al., 1978). A digital computer study using simulated data with 
random error indicated no difference in the precision and accuracy of parameter esti- 
mation when several different equations were fitted to the data, each set of which related 
to the same model (Wong et  al., 1979). 
In 1974, AUTOAN, a decision-making pharmacokinetic program, was made available, 
and subsequently described (Wagner, 1975a). This program is really a large so-called 
DFUNC subroutine of the digital computer program NONLIN (Metzler, 1969). 
5.6. BIOAVAILABILITY 
Factors affecting the magnitude of the 'first pass' effect were discussed in detail (Riegel- 
man and Rowland, 1973; Benet, 1978) and the effect of the route of administration and 
the distribution of the drug on drug action were reviewed (Benet, 1978). A method was 
proposed for estimating the bioavailability of a drug whose elimination from a one- 
compartment body model occurs by one or more apparent first-order processes in 
parallel with one capacity-limited or Michaelis-Menten pathway (Martis and Levy, 
1973). Some new methods of estimating drug bioavailability under single dose and quasi- 
and nonsteady-state conditions were described in detail (Kwan and Till, 1973; Till et  al., 
1974, Kwan et  al., 1975). The use of data derived from the monitoring of the time 
variation of the intensity of a pharmacological response or effect following dosing has 
been championed by Smolen; such data can be utilized in bioavailability assessment 
(Smolen and Wiegand, 1973; Smolen, 1976a,b). An excellent example of how to differen- 
tiate between liver and gastrointestinal 'first pass' metabolism was reported (Cotler et  al., 
1976). Albert et  al. (Albert e t  al., 1979) showed that within-lot and between-lot uniformi- 
ties in bioavailability of methylprednisolone from commercial tablets are very similar, 
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suggesting that the observed variability in serum methylprednisolone concentrations was 
not the result of manufacturing variables. Some important aspects of estimating bioavail- 
ability of digoxin were discussed and illustrated (Wagner and Ayres, 1977). 
5.7. DRUG INTERACTIONS 
Rowland and Matin pointed out that since many drug~lrug pharmacokinetic 
interactions are dependent on the concentrations of the interacting species, the degree of 
interaction should be a graded phenomenon varying with the drug and/or metabolite 
concentration and thus drug administration and time. They discussed the interaction of 
phenobarbital with griseofulvin, sulfaphenazole with tolbutamide, and warfarin with 
phenylbutazone and stressed the importance of measuring not only intact drug adminis- 
tered but also metabolites in drug interaction studies (Rowland and Matin, 1973). Levy 
reviewed some pharmacokinetic approaches to the study of drug interactions (Levy, 
1976). A steady-state blood concentration method for detecting and quantitating drug- 
drug interactions was illustrated by the ethanol-propranolol interaction in the cat 
(Wagner et al., 1976b). Gillette and Pang used a blood flow rate-limited (physiologically- 
based) type of model to indicate the possible effects of drug interactions on measurable 
variables (Gillette and Pang, 1977). 
5.8. CLINICAL PHARMACOKINETICS 
As indicated in a previous section of this chapter the number of published articles 
specifically in the clinical pharmacokinetics area had reached at least a rate of 400-500 
articles per year by 1979. In writing this section no attempt has been made to review 
and/or evaluate this large body of literature or to choose what the author considers to be 
the most important articles, as was done in most of the other sections of this chapter. 
Rather, the few articles discussed below are merely examples of the literature. 
One type of clinical pharmacokinetic article may be classified as educational, where 
the purpose is to acquaint those unfamiliar with pharmacokinetics with the terminology 
and examples. This type is .exemplified by the articles of Gibaldi and Levy entitled 
Pharmacokinetics in Clinical Practice, which were published in the Journal of  the 
American Medical Association (Gibaldi and Levy, 1976a,b), and by the article of Dettli, in 
which he discussed examples of pharmacokinetic analyses which influence the practice of 
therapeutics (Dettli, 1973). 
Another type of article consists of a compilation and quick reference. An example here 
is the article of Pagliaro and Benet who critically compiled values of terminal half-lives, 
percent drug excreted unchanged in urine, and changes of half-life in patients with renal 
and hepatic dysfunction (Pagliaro and Benet, 1975). 
A third type of article is one directed at describing pharmacokinetic monitoring of a 
drug during therapy. The specialty of clinical pharmacokinetics encompasses the rational 
employment of theoretical pharmacokinetics to evolve practical guidelines for drug ther- 
apy in patients, with subsequent assessment of the utility and appropriateness of such 
guidelines by monitoring serum concentrations. The article of Koup et al. describing a 
system for guiding and monitoring theophylline therapy serves as an example in this area 
(Koup et al., 1976). 
A fourth type of article is the review, frequently bearing a title such as 'The Clinical 
Pharmacokinetics of Drug X'. The issues of the journal Clinical Pharmacokinetics have 
carried many such reviews and these now are too numerous to be listed. 
The fifth type of article is the 'original literature' type where new experimental data are 
presented. An example here is the article by Klotz et al. who reported on the effect of age 
and liver disease on the disposition and elimination of diazepam in adult men (Klotz et 
al., 1974). The prolongation of the apparent elimination half-life of diazepam was shown 
to be caused by two different mechanisms: (1) in liver disease metabolic clearance is 
decreased; (2) in aging the volume of distribution of the drug is increased. The authors 
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also explored the role of altered disposition in the frequency of side effects resulting from 
administration of diazepam. 
Pharmacokinetics should not be viewed in isolation, but rather as a tool to improve 
rational drug therapy, The rapid growth of pharmacokinetics during the past two 
decades has been made possible largely by vast improvements in analytical methodology. 
Listed below are ideas (see Acknowledgement) on the possible future use of pharmaco- 
kinetics in patient care. Some of these are being performed at the time of writing, but 
perhaps their use will become more widespread in the future. 
Future use of pharmacokinetics for patient care include: 
(1) Individualization of patient dose and dosage regimen. 
(2) Use of pharmacokinetic parameters as variables to guide rational synthesis and 
testing of new chemotherapeutic agents. 
(3) Development and use of non-invasive methods of assessing drug concentrations in 
patients. 
(4) Characterization and prediction of the time course of the intensity of pharmacolo- 
gic effects. 
(5) Continuation and improvement in the use of pharmacokinetics in the assessment of 
the bioavailability of a drug, from different dosage forms and the same dosage form made 
by two or more manufacturers, or given by different routes. 
(6) More emphasis on a comparison of intra- and inter-subject variabilities in pharma- 
cokinetic parameters. 
(7) Possible development of a 'sub-therapeutic cocktail' of various compounds, fol- 
lowed by routine analysis of biological samples taken from the patient, to obtain profiles 
of the compounds which would reflect the magnitudes of pharmacokinetic parameters 
which, in turn, would be useful in guiding therapy in the drugs. 
(8) Aid in determining the mechanism of drug-drug interactions and their avoidance. 
(9) Use of pharmacokinetic principles to guide in the use of some drugs in some 
patients. 
(10) Development of pharmacokinetic laboratories and/or centers throughout the 
world to guide physicians in their use of drugs. 
(11) Prediction of pharmacokinetics of drugs in man from results obtained in animals, 
using physiologically-based models and scale-up factors. 
(12) Use of pharmacokinetics as a diagnostic tool, such as in acetylation testing. 
(13) Improvement in the quality and specificity of drug use in patients. 
(14) Identification of optimum methods to accelerate drug elimination from the body 
in cases of toxicity and/or overdosage. 
(15) Identification of active metabolites of drugs and quantitation of their role in 
producing the overall response following drug administration. 
(16) Development and use of sophisticated digital computer programs to obtain popu- 
lation estimates of pharmacokinetic parameters and their variabilities, which, in turn, 
would aid in drug therapy of other patients. 
(17) Education of physicians and other health professionals concerning what pharma- 
cokinetics can do in improving the rational use of drugs. 
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